Poly(ADP-ribose) polymerase: A new therapeutic target?

Domokos Gero, Csaba Szabo

    Research output: Contribution to journalReview articlepeer-review

    39 Scopus citations


    Purpose of review To overview the emerging data in the literature showing the role of poly(ADP-ribose) polymerase (PARP) in the pathogenesis of critical illness. Recent findings PARP, an abundant nuclear enzyme involved in DNA repair and transcriptional regulation, is now recognized as a key regulator of cell survival and cell death in response to noxious stimuli in various forms of cardiovascular collapse. PARP becomes activated in response to oxidative DNA damage and depletes cellular energy pools, thus leading to cellular dysfunction in various tissues. The activation of PARP may also induce various cell death processes, and promotes an inflammatory response. In circulatory shock PARP plays a crucial role both in the development of early cardiovascular dysfunction and in the delayed systemic inflammatory response syndrome with associated multiple organ failure. Inhibition of PARP activity is protective in various models of circulatory shock. Summary A solid body of literature supports the view that PARP is an important target for therapeutic intervention in critical illness.

    Original languageEnglish (US)
    Pages (from-to)111-121
    Number of pages11
    JournalCurrent Opinion in Anaesthesiology
    Issue number2
    StatePublished - Apr 1 2008


    • Cardiovascular
    • Dysfunction
    • Inflammation
    • Peroxynitrite
    • Shock

    ASJC Scopus subject areas

    • Anesthesiology and Pain Medicine


    Dive into the research topics of 'Poly(ADP-ribose) polymerase: A new therapeutic target?'. Together they form a unique fingerprint.

    Cite this